Introduction {#s1}
============

Inherited retinal diseases are an important cause of blindness and are estimated to affect 2 million people worldwide \[[@R1]\]. Despite this there is no available treatment for the majority of patients. Gene therapy could potentially offer a cure. By introducing, silencing, or editing genes involved in the pathogenesis of these diseases, progression can be halted or even reversed \[[@R2]\]. The eye has been at the forefront of gene therapy as it has several useful qualities. Firstly, the eye is immune-privileged meaning a higher tolerance of introduced antigens \[[@R3]\]. Secondly, the presence of the blood retina barrier reduces the likelihood that viral vectors introduced into the eye during gene therapy will migrate to other areas \[[@R4]\]. This lowers the risk associated with potential off-target effects of treatment. Thirdly, the target site for gene therapy is easily accessible via current ophthalmic techniques and only requires local anaesthetics. This access means that the amount of virus required for retinal transduction is minimal compared to systemic targets such as the liver \[[@R5]\]. 

Retinal gene therapy has traditionally involved gene replacement, a technique known as gene augmentation \[[@R6],[@R7]\]. The targeted diseases are caused by a lack of wild type function of a gene, and therefore supplying the missing gene may revert the pathology towards a normal phenotype, particularly when applied before the onset of cell death. While gene augmentation offers a promising outcome for patients with loss-of-function mutations, it cannot be used to treat dominant gain-of-function mutations. In these cases, the pathogenic mutation will need to be silenced or corrected for normal cell function to return. This presents a greater challenge than gene augmentation because the introduction of molecular inhibition into a host cell brings the possibility of off-target effects. Prior to the CRISPR/Cas9 system, gene editing at the DNA level was directed by zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs). These techniques both have their disadvantages, with ZFNs having a low on-target efficiency and difficulty locating a potential target site \[[@R8],[@R9]\], and TALENs being very large and therefore difficult to deliver to the cell \[[@R10]\]. The discovery of the CRISPR/Cas9 system has been revolutionary as it is simple to design and implement. Gene editing requires only three components: the presence of a short sequence, roughly 3 to 8 bp (the PAM site) adjacent to the target site, the endonuclease protein Cas9, and a customized piece of RNA which directs Cas9 to the target site for DNA cleavage \[[@R11]-[@R13]\]. 

CRISPR/Cas9 Mechanism  {#s2}
======================

CRISPR/Cas9 is a naturally occurring system that has evolved in bacteria and archaea as a method of evading viral infection. The microorganisms store copies of short sections of viral DNA in their genome which are transcribed into RNA called CRISPR RNA (crRNA). The crRNA forms a complex with a second piece of RNA, the trans-activating crRNA (tracrRNA), and CRISPR-associated protein 9 (Cas9), which are all encoded in the bacterial genome. If this complex encounters viral (bacteriophage) DNA which is complementary to the crRNA sequence it will bind to it. Cas9 is an endonuclease which cleaves double-stranded DNA, slicing through the viral DNA and preventing transcription \[[@R11],[@R13]\]. 

Researchers soon realized that this system could be used for targeted gene editing in the genome of a chosen cell. By supplying a cell with Cas9, tracrRNA, and a crRNA specific to the target, Cas9 will cleave the region of interest. Since this discovery, the crRNA and tracrRNA have been artificially engineered into one single guide RNA (sgRNA) which can be customized to the target \[[@R13]\]. The final component required for CRISPR/Cas9-mediated gene editing is the presence of a protospacer adjacent motif (PAM) site adjacent to the target region \[[@R14]\]. A PAM site is a short DNA sequence (usually between 3 to 8 bp in length) that Cas9 binds to, inducing the double-stranded break approximately 3 bp upstream of the PAM \[[@R13]\]. These sites are naturally present on viral DNA and the exact sequence of the PAM is dependent on the species the Cas9 is isolated from. The most commonly used Cas9 to date has been SpCas9 from *Streptococcus pyogenes*, which requires a PAM of 5'-NGG-3', where N is any nucleotide \[[@R15]\]. A number of bioinformatic programs are available which screen DNA sequences for PAM sites. Once a suitable PAM is selected, the sgRNA is designed to contain a region homologous to the sequence immediately upstream of the PAM (typically 18 to 25 bp long). By supplying a cell with the specific sgRNA and an active Cas9 protein, a double-stranded break will be induced at the site. 

When a double-stranded break occurs in a host genome the cell will attempt to repair it using one of two processes: Non-Homologous End Joining (NHEJ) or Homology-Directed Repair (HDR) ([Figure 1](#F1){ref-type="fig"}). In the absence of any homologous (identical complementary) DNA sequence, the cell will undergo NHEJ. Since there is no DNA template for repair, this process is somewhat random and hence extremely error prone, resulting in small insertions or deletions (indels) at the cleavage site. If these indels result in a frame-shift mutation in an exonic region, this can disrupt the gene, creating a non-functional protein. The HDR pathway allows researchers to perform precise edits of host DNA. Following a double-stranded break, any DNA molecules with a high level of homology to the target region will be substituted into the genome. By supplying a donor DNA molecule containing the desired mutation between two regions of homology to the target site (homologous arms), this increases the chances of the HDR pathway being used and the mutation being incorporated into the cell. 

A third use of the CRISPR/Cas9 system involves introducing an artificially-engineered inactive version of Cas9 (dCas9) to alter the expression level of a gene at a transcriptional level, a technique called CRISPR interference (CRISPRi). dCas9 retains the ability to bind to DNA via the sgRNA and PAM site, but has no cleavage activity. By targeting dCas9 to regulatory elements of the target gene it can sterically inhibit transcriptional machinery such as transcription factors or RNA Polymerase, decreasing transcription of the gene \[[@R16]\]. This effect can be enhanced by fusing dCas9 with a transcriptional inhibitor, such as Krüppel associated box \[[@R17]\]. Alternatively, fusing dCas9 with a transcriptional activator can upregulate expression via CRISPR activation (CRISPRa) \[[@R18]\] ([Figure 1](#F1){ref-type="fig"}). 

Treatment Strategies {#s3}
====================

As knowledge of the CRISPR/Cas9 system increases, different applications of the technique are being developed. Many of these have already been applied *in vivo*for the treatment of retinal diseases, demonstrating its potential in gene therapy ([Table 1](#T1){ref-type="table"}). 

Silencing/Targeting the Pathogenic Mutation {#s3a}
-------------------------------------------

The most common use of CRISPR/Cas9 in the treatment of eye diseases is the direct silencing of dominant negative pathogenic mutations via the NHEJ pathway. If the target gene mutation has a dominant negative effect (*e.g*. Rhodopsin), then disrupting the mutant allele will restore wild type functionality of the gene. In contrast, if the target gene is haploinsufficient (*i.e*. two wild type alleles are needed to prevent the disease phenotype *e.g*. PAX6), or the CRISPR/Cas9 strategy is not allele-specific (knocking out both the wild type and mutant copy of the gene), then additional wild type copies of the gene can be reintroduced to the cells via gene augmentation \[[@R19]\]. 

Allele-specific CRISPR/Cas9 binding can be achieved in two ways: sgRNA design or novel PAM sites ([Figure 2](#F2){ref-type="fig"}). While the specificity of Cas9 is variable (see Off-target Effects), many papers have reported that a one bp difference in the DNA target sequence is sufficient to drive allele-specific cleavage. This allows just the mutant allele to be targeted by designing the sgRNA to the region containing the mutation \[[@R20],[@R21]\]. Alternatively, some mutations will generate a novel PAM site that is not present on the wild type allele, ensuring the Cas9 only binds to the target strand. While it may seem unlikely that a novel PAM site will be generated, the wide range of Cas9 species and associated PAM sites available (see [Table 2](#T2){ref-type="table"}) makes this possible, with one researcher reporting that of 76 known missense mutations associated within four retinal dystrophy genes, 36 percent produced a novel PAM site for SpCas9 \[[@R22]\]. Both Courtney *et al*. (2016) and Bakondi *et al*. (2016) used novel PAM sites to target allele-specific disruption of their mutant gene in the treatment of Meesman's epithelial corneal dystrophy and retinitis pigmentosa (RP), respectively \[[@R22],[@R23]\]. Courtney *et al*. (2016) reported successful *in vivo*mutant gene disruptionin 5 of 13 clones (though this is too low to be therapeutically viable), while Bakondi *et al*. (2016) reported target cleavage efficiencies of 33 percent and 36 percent in two CRISPR-edited rats, corresponding with a partial phenotypic rescue. Neither paper reported a reduction in the wild type allele expression, demonstrating that allele-specific knock down is possible using CRISPR/Cas9. 

Another method of silencing pathogenic mutations is the removal of sections of DNA using a pair of sgRNAs which bind to either side of the target region. Following excision, the genomic DNA is repaired using the NHEJ pathway \[[@R24]\]. Ruan *et al*. (2017) proposed this method as a treatment for Leber Congenital Amaurosis type 10 (LCA10) caused by an intronic mutation in intron 26 of *CEP290* (IVS26 mutation) \[[@R25]\]. This mutation generates a premature stop codon in half of all transcripts due to aberrant splicing, resulting in reduced CEP290 activity \[[@R26]\]. This would normally be a viable candidate for gene augmentation but*CEP290*has a large 7440 bp open reading frame which exceeds adeno-associated viral (AAV) packaging capacity, and *CEP290* over-expression is cytotoxic to photoreceptors \[[@R27]\]. While there is no mouse model of human IVS26, mouse *Cep290*intron 25 is homologous to human *CEP290*intron 26 and was successfully removed from wild type mice retinal cells *in vivo*in 7.5 percent to 26.4 percent of reads. Since this region has no role in coding but simply directs splicing there is no need for a gRNA template for repair \[[@R25]\]. This dual sgRNA approach has also been used to excise a small 24 bp region surrounding the*RHO*P23H mutation with the aim to treat RP via gene silencing and augmentation \[[@R19]\]. 

Insertion of DNA  {#s3b}
-----------------

As well as inactivation of pathogenic mutations, CRISPR/Cas9 provides the opportunity to insert DNA at a specific locus to restore wild type functioning of a gene. Though this traditionally utilizes the HDR pathway \[[@R28]-[@R31]\], Suzuki *et al*. (2017) demonstrated a modified method of gene insertion via the NHEJ pathway, named Homology-Independent Targeting Integration \[[@R32]\]. Using this strategy, they successfully inserted the missing exon 2 into intron 1 of *Mertk*in the Royal College of Surgeons rat model of RP. This resulted in increased levels of *Mertk*mRNA and protein levels than the untreated animals, corresponding with improved outer nuclear layer (ONL) thickness and ERG responses indicating a partial rescue of the phenotype. 

Treating Disease Symptoms  {#s3c}
--------------------------

Retinal diseases with complex genetic and environmental risk factors may be unsuitable for traditional gene therapy approaches. In these cases, genetic modification may be used to reduce the severity of the disease by targeting genes involved in its pathogenesis. This approach was taken by Kim *et al*. (2017) for the treatment of wet age-related macular degeneration (AMD) \[[@R33]\]. In wet AMD, choroidal neovascularisation (CNV) leads to deterioration of central vision \[[@R34]\]. Kim *et al*. (2017) used CRISPR/Cas9 to disrupt *Hif1a*(crucial to the development of CNV \[[@R35]\]) in wild type mice who later underwent laser-induced CNV. The AAV-*Hif1a*treated eyes demonstrated a 20±4 percent reduction in area of CNV compared to the uninjected control, with no deleterious effects on cone function, demonstrating its potential as a therapeutic intervention. 

Cellular Reprogramming {#s3d}
----------------------

Therapeutic cellular reprogramming involves converting cells which are sensitive to a mutation to a functionally related cell type that is less affected by the mutation in the hopes of reducing the disease severity. This technique has potential in the treatment of retinal dystrophies due to the high levels of heterogeneity existing between diseases. RP, for example, is characterized by loss of rod cells leading to secondary cone cell death, but to date there have been over 3000 causative mutations in over 60 genes identified for this disease. This makes it difficult to develop gene therapy strategies to treat large cohorts of patients \[[@R36]\]. Two papers published within two months of each other sought to utilize CRISPR/Cas9 to induce cellular reprogramming of mutationally-sensitive rod cells to cone cells within four models of RP \[[@R37],[@R38]\]. *Nrl*and *Nr2e3*are transcription factors involved in the differentiation and regulation of rod cells. Absence of either of these transcription factors is known to cause rod cells to develop a cone cell fate \[[@R39],[@R40]\]. CRISPR/Cas9 caused targeted gene disruption of either *Nrl*or *Nr2e3*via subretinal injection of mice between P7 and P14. Both researchers observed a downregulation of rod-specific genes and an up-regulation of some cone-specific genes. This occurred alongside significant rescue of photoreceptor functioning. Zhu *et al*. (2017) reported significantly improved cone and rod function with preserved ONL, and Yu *et al*. (2017) reported some functional cone and rod activity at 4 months of age, a month after rod death is usually complete in their tested mouse lines. Both authors conclude that cellular reprogramming of rods to cones is a promising area of further study for retinal disease treatment. 

Stem Cells  {#s3e}
-----------

The use of gene modification has promise as an early intervention strategy to prevent retinal degeneration, but for patients with advanced disease progression it offers little hope of a cure. CRISPR/Cas9 has the potential to correct pathogenic mutations in patient's own induced pluripotent stem cells (iPSCs). These can be differentiated into the required cell type and re-implanted into the eye. This route has the potential to be tailored to rare mutations found in small populations or individuals. Bassuk *et al*. (2016) demonstrated this in iPSCs derived from two brothers carrying a novel *RPGR*mutation \[[@R41]\]. iPSCs were differentiated from fibroblasts and the HDR pathway used to correct the c.3070G\>T mutation in 13 percent of cells, a higher rate than previous CRISPR/Cas9 iPSC correction studies \[[@R42]\]. The use of retinal grafts to integrate stem cell-derived cells has demonstrated cell survival, safety, and efficacy in clinical trials, offering a potential therapeutic route for CRISPR/Cas9-corrrected iPSC therapies \[[@R43],[@R44]\]. 

Challenges to Clinical Application {#s4}
==================================

Efficiency of Gene Editing  {#s4a}
---------------------------

While *in vitro*gene editing for retinal diseases using CRISPR/Cas9 often reports high rates of gene disruption *in vitro* (up to 82 percent \[[@R19]\]), the rates of successful gene editing *in vivo*are lower (up to 33 percent \[[@R19]\]). This success rate is highly variable between studies and may be dependent upon the type of Cas9 used \[[@R25],[@R33]\], the design of the sgRNA, the target cell type, the delivery method, and the *in vivo*model amongst other factors \[[@R37],[@R38]\]. One study using AAV-delivered CRISPR/Cas9 found a 50 percent *in vitro*deletion rate in neuro-2a cells which was reduced to 7.5 percent to 26.4 percent in treated retinas *in vivo* \[[@R25]\]. Though these rates are quite low, some diseases would not require complete silencing of the mutant gene. Meesmann's epithelial corneal dystrophy, for example, can be alleviated with a 50 percent reduction in mutant allele expression levels \[[@R22]\]. Other studies suggest that only a partial gene correction can result in a significant therapeutic impact \[[@R45]\]. Regardless of the rate of the CRISPR/Cas9 gene editing, *in vivo*studies are reporting improvements in disease phenotypes, which could have significant impacts on a patient's quality of life \[[@R32],[@R33],[@R37],[@R38]\]. 

Off-target Effects  {#s4b}
-------------------

As with any genetic modification technique, there are concerns regarding the off-target effects of CRISPR/Cas9. Non-specific gene editing could remove essential genes or disrupt tumor suppressing genes causing cancers \[[@R10]\]. It is therefore vital that any genetic modification methods are specific and off-target effects are predictable. As Cas9 binding is dependent upon both the presence of a PAM site and upstream homology to the sgRNA sequence, bioinformatic programs can be used to predict off-target effects. Encouragingly, some papers reported that a one nucleotide discrepancy in the sgRNA binding region prevents indel formation \[[@R20],[@R21]\] and most studies demonstrate no off-target effects at the most probable sites. In studies employing whole genome screening, off-target effects are rare (up to several hundred), with some studies reporting only one off-target effect within the entire genome \[[@R46]-[@R50]\]. 

Despite this, off-target effects have been varied across studies, with some papers reporting DNA editing with a 5-bp discrepancy between the sgRNA and target region \[[@R12],[@R51]\]. The effect of base pair mismatch between the sgRNA and the target have been showed to be highly influenced by the distance between the mismatch and the PAM site, with PAM-distal mismatches being more tolerated than PAM-proximal mismatches \[[@R11]-[@R13],[@R52]\]. There have also been incidents of reduced gene expression in a site with sgRNA homology but no PAM site \[[@R22]\]. The cleavage sites can also vary between *in vitro*and *in vivo*studies \[[@R53]\], making it difficult to accurately predict off-target effects. 

Two artificial Cas9 molecules have been created with the aim of reducing off-target effects: nickases and high-fidelity Cas9 (SpCas9-HF1). Nickases are modified Cas9 molecules which can only cleave one strand of DNA. To induce a double-stranded break into the DNA for gene modification, one nickase must bind to either strand of DNA (each guided by an sgRNA) in close proximity. The use of nickases can reduce off-target effects by 50 to 1500 times compared to SpCas9 at the same site, and has been successfully used to disrupt genes in mouse embryos \[[@R54]\]. SpCas9-HF1 is a modified SpCas9 that has four altered amino acids \[[@R55]\]. These result in decreased non-specific binding and have been reported to have no detectable off-target effects while efficiency remains comparable to the wild-type SpCas9. 

It has been proposed that reducing the temporal expression of Cas9 will reduce the off-target effects, and so the use of a self-limiting Cas9 construct has been explored. In a self-limiting Cas9, the Cas9 expression system carries at least one copy of the sgRNA target site. The sgRNA will guide the Cas9 to both the genomic target site and the Cas9 vector, inactivating it and halting Cas9 transcription. This has been shown to successfully reduce Cas9 expression to negligible levels while maintaining targeted gene editing *in vitro* \[[@R25]\]. While limiting transgene expression may have advantages from a regulatory approach, its usefulness is debated, with some papers reporting that long-term Cas9 expression is not associated with an increased risk of off-target effects \[[@R33]\]. 

Heterogeneity of Disease  {#s4c}
-------------------------

Despite retinal dystrophies having many characteristics which make them a useful target for gene therapy, the heterogeneity of these diseases remain a challenge for widescale treatment therapies. Many diseases have hundreds of identified causative mutations (over 100 variants in over 20 loci for LCA \[[@R56],[@R57]\]), with some mutations specific to singular families or even individuals \[[@R36],[@R41]\]. 

Cellular reprogramming, targeting of disease symptoms, and iPSC-derived retinal grafts (described in more detail in Treatment Strategies), have been suggested as potential solutions to this problem. Cellular reprogramming and targeting disease symptoms via CRISPR/Cas9 can be applied to patients without an identified causative mutation, but these are still in early stages of research \[[@R37],[@R38]\]. Stem cell derived retinal grafts, alternatively, have been used in multiple clinical trials and have demonstrated efficacy and safety \[[@R43],[@R44]\]. Using patients own iPSC would allow the pathogenic mutation to be corrected *in vitro*before differentiation into photoreceptors. This would allow rare mutations to be targeted on a case-by-case basis and detailed screening of on and off-target effects to be conducted before transplantation into the eye. 

Rates of HDR in the Eye {#s4d}
-----------------------

Precise gene correction with CRISPR/Cas9 relies on the HDR pathway. While HDR occurs most frequently in the late S and G2 stages of the cell cycle phase, retinal cells are post-mitotic, and therefore the HDR rate is low. Some studies have concluded these HDR rates are currently too low to have a therapeutic value. 

The use of small molecules to suppress the NHEJ pathway and force cells to repair the double-stranded break with HDR has demonstrated efficacy in increasing the rates of HDR. SCR7 is an inhibitor of DNA ligase and has been shown to increase rates of HDR by 5-fold and 19-fold in separate *in vitro*studies \[[@R31],[@R58]\]. It was subsequently used to enhance CRISPR/Cas9 editing of the HSV-1 viral genome and found to increase HDR rates by over 10-fold \[[@R59]\]. 

In 2016, a new CRISPR/Cas9 technique was described: Homology-Independent Targeted Integration. This allows precise gene knock-in without the HDR pathway. In this, the DNA insert is flanked by Cas9 cleavage sites. Following cleavage of both the genomic DNA target site and the DNA insert, the insert will be ligated into the genomic target site via NHEJ. The DNA insert is designed in such a way that integration in the reverse orientation will generate a CRISPR/Cas9 cleavage site allowing it to be removed by Cas9 again until it is integrated in the correct orientation. This was found to have higher knock-in efficiency than HDR both *in vitro* in HEK293 cells and *in vivo*,where it was used to correct a rat model of RP \[[@R32]\]. 

Conclusion {#s5}
==========

CRISPR/Cas9 is an exciting area of study which is revolutionizing all aspects of genetics, from basic biology to potential medical interventions. Due to its favorable characteristics and track record in gene therapy, retinal diseases are likely to be one of the earliest targets of CRISPR/Cas9 mediated therapy. *In vivo* studies demonstrate a promising future for CRISPR/Cas9 therapies, with rescue effects seen across a range of diseases. Its versatility lends itself to a variety of approaches to tackle these debilitating diseases. Despite all this, there is still a long way to go. HDR rates are currently below the therapeutic range, although there are avenues around this being explored. Reduction of off-target effects remains a priority as if CRISPR/Cas9 is to have a future in gene therapy, its off-target effects must be predictable and minimized. 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###### *In vivo* experiments utilizing CRISPR/Cas9 for therapeutic interventions for retinal diseases.

  **Reference**                       **Disease**                              **Gene Target**                                      **Methodology**                                                                  **Results**                                                                            **Cas9 species**
  ----------------------------------- ---------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------
  Ruan *et al*. 2017 \[[@R25]\]       LCA10                                    Removal of intron 25 of CEP290                       Subretinal injection of dual AAVs into mice                                      Successful gene editing in 7.5% to 26.4% of reads between treated eyes                 SpCas9
  Kim *et al*. 2017 \[[@R33]\]        Wet age-related macular degeneration     Disruption of *Hif1a*                                Subretinal injection of single AAV into CNV-induced mice                         20±4% reduction in CNV                                                                 CjCas9
  Courtney *et al*. 2016 \[[@R22]\]   Meesman's epithelial corneal dystrophy   Allele-specific disruption of *KRT12-*L132P          Intrasomal injection of Cas9-GFP and gRNA in *KRT12-*L132P mice                  *KRT12-*L132P disruption in 38% of isolated clones                                     SpCas9
  Suzuki *et al*. 2016 \[[@R32]\]     Retinitis pigmentosa                     Insertion of missing *Mertk*exon 2                   Subretinal injection of dual AAVs into Royal College of Surgeons rat model       Increased *Mertk*mRNA and protein levels. Improved ONL preservation and ERG response   SpCas9
  Latella *et al*. 2016 \[[@R19]\]    Retinitis pigmentosa                     Removal of 24 bp region of *Rho* at the P23H locus   Subretinal injection and electroporation of plasmid in *Rho*^-/-^P23H^Tg^ mice   16% of reads contained the desired 24 bp deletion                                      SpCas9
  Yu *et al*. 2017 \[[@R37]\]         Retinitis pigmentosa                     Disruption of *Nrl*                                  Subretinal injection of dual AAVs into Rhodopsin KO, Rd10, RHO-P347S mice        Delayed loss of rod function and prolonged cone survival                               SpCas9
  Zhu *et al*. 2017 \[[@R38]\]        Retinitis pigmentosa                     Disruption of *Nrl*or *Nr2e3*                        Subretinal injection of dual AAV into Rd10 and Rd1 mice                          Significant rescue and restoration of both rod and cone function                       SpCas9
  Bakondi *et al*. 2016 \[[@R23]\]    Retinitis pigmentosa                     Allele-specific disruption of *Rho*^S334^            Subretinal injection and electroporation of plasmid in S334ter-3 rats            Increased retinal preservation and 35% increased VA                                    Human codon optimized SpCas9 (hCas9)

###### Cas9 species and their associated PAM site sequences.

  **Species**                    **Cas9**      **PAM site**   **Reference**
  ------------------------------ ------------- -------------- --------------------------------------
  *Streptococcus pyogenes*       SpCas9        NGG            Anders *et al*. 2014 \[[@R15]\]
  Synthetically modified         SpCas9 VQR    NGAN or NGNG   Kleinstiver *et al*. 2015 \[[@R55]\]
  Synthetically modified         SpCas9 EQR    NGAG           Kleinstiver *et al*. 2015 \[[@R55]\]
  Synthetically modified         SpCas9 VRER   NGCG           Kleinstiver *et al*. 2015 \[[@R55]\]
  *Staphylococcus aureus*        SaCas9        NNGRRT         Ran *et al*. 2015 \[[@R60]\]
  *Campylobacter jejuni*         CjCas9        NNNNACAC       Kim *et al*. 2017 \[[@R33]\]
  *Neisseria meningitidis*       NmCas9        NNNNGATT       Hou *et al*. 2013 \[[@R61]\]
  *Streptococcus thermophilus*   St1Cas9       NNAGAAW        Müller *et al*. 2016 \[[@R62]\]
  *Streptococcus thermophilus*   St3Cas9       NGGNG          Müller *et al*. 2016 \[[@R62]\]

![**Applications of CRISPR/Cas9 for transcriptional regulation and genomic modification.**Following Cas9 binding, cleavage of both DNA strands allows DNA modification. In the absence of any homologous sequences, the cell will undergo non-homologous end joining, resulting in small insertions or deletions around the cut site. If donor DNA is supplied which has homologous arms matching the genomic DNA it will be incorporated into the genome via homology directed repair. Catalytically inactive dCas9 can be targeted to a promoter to alter transcriptional regulation. Fusing a transcriptional activator to dCas9 will upregulate gene expression (termed CRISPR activation) while fusing a transcriptional repressor to dCas9 will downregulate gene expression (termed CRISPR interference).](yjbm_90_4_533_g01){#F1}

![**Allele-specific Cas9 targeting via sgRNA design or novel PAM sites.** Cas9 can be targeted to the mutant allele by designing the sgRNA to the region containing the mutation. The discrepancy between the sgRNA sequence and wild type may be sufficient to prevent binding. If the target mutation generates a novel PAM site this will allow Cas9 binding on the mutant but not the wild type strand.](yjbm_90_4_533_g02){#F2}
